Oregon is first state to permit supervised use of psilocybin, signaling shift in stigma CYBN entering phase 2 of clinical study of sublingual psilocybin for the potential treatment of MDD Newly discoverable data from psychedelic studies may potentially create entirely new marketplace of safe and effective drugs Cybin (NEO: CYBN), a mushroom life sciences company, … Continue reading “Cybin Inc. (NEO: CYBN) Targets Major Depressive Disorder with Breakthrough Therapy”
Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushrooms sector, today announced that it is commencing a study on the formulation and manufacturing of psilocybin-based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. … Continue reading “NetworkNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) Commences Study to Further Knowledge in Psilocybin, Associated Delivery Mechanisms”
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, on Tuesday announced the unaudited financial results of Clarmin Explorations Inc. (now Cybin Inc.) for the three month period ended Oct. 31, 2020. According to the update, a copy of the consolidated financial statements prepared in accordance with International Financial Reporting Standards, as … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Q1 Results for Clarmin Explorations”
Cybin (NEO: CYBN), a mushroom life science company, is set to leverage opportunity amid growing research that demonstrates the significant role psilocybin could play in alleviating symptoms of major depression. According to a recent study conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry,” only two doses of psilocybin accompanied with psychotherapy may lead … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) on Track to Leverage Psychedelics to Target Depression”
Related Editorial More than 700 million people worldwide are affected with some form of mental illness, addiction or eating disorder, representing about 13% of total disease burden. In reality, the worldwide picture is a bit murky, considering the high frequency of nondiagnosis as well as lack of treatment, even in the most developed countries. Advances … Continue reading “NetworkNewsAudio – Cybin Inc. (NEO: CYBN) Establishing Psychedelic-based Drug Discovery Platform to Treat Mental Health Disorders”
Study published in “JAMA Psychiatry” reveals significant benefits of psilocybin for patients with major depression Most participants reported improvements; half experienced remission after only four weeks As an early entrant in the field, Cybin looks well placed to capitalize on growing traction that psychedelics gain as potential treatment of mental health conditions Only two doses … Continue reading “Cybin Inc. (NEO: CYBN) on Right Path; Johns Hopkins Study Shows Psilocybin Positive Impact on Major Depression”
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, today announced the close of its acquisition of 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately US$15.75 million). “We are thrilled to join forces with Adelia. We see this acquisition as potentially advancing Cybin’s ability to innovate our … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) Joins Forces with Adelia Therapeutics to Potentially Address Treatment Gaps Beyond Major Depressive Disorder”
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, recently announced its entry into a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately US$15.75 million) in an all-stock transaction. The transaction is subject to the satisfaction or waiver of customary conditions, including receipt … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Agreement to Acquire Adelia Therapeutics”
UC Berkeley and other prominent academic institutions, including Johns Hopkins University in Maryland and Imperial College in London, are accelerating scientific research of psilocybin by launching a new center focusing on the compound (https://nnw.fm/ooMHq). Cybin (NEO: CYBN), a mushroom life science company, is positioned amid this growing research interest that is bringing psilocybin into mainstream. … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) Positioned as Early Entrant in Rapidly Growing Field of Psychedelics”
Cybin (NEO: CYBN) CEO Doug Drysdale was featured on a recent episode of TraderTV Live. Broadcast live from the DTTW trading floor, TraderTV Live is the first and only professional trading show on YouTube Live. During the show, Drysdale discussed Cybin’s work on psychedelic medical research, including the company’s current phase 2 study. He also … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) CEO Talks Company’s Psychedelic Research, Plans on Live Trading Show”
